Intravenous showed no clear difference in adverse events: hair loss compared with oral cyclophosphamide (low certainty).
Intravenous may leads to lower adverse events: all infections compared with oral cyclophosphamide (low certainty).
It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).
Cyclophosphamide showed no clear difference in relapse at 12 months compared with chlorambucil (low certainty).
Cyclophosphamide showed no clear difference in relapse at 24 months compared with chlorambucil (low certainty).
Rituximab showed no clear difference in adverse effects: severe infection compared with placebo or control (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Cyclophosphamide may leads to lower adverse effects: lymphopenia compared with chlorambucil (low certainty).
Cyclophosphamide may leads to lower adverse effects: thrombocytopenia compared with chlorambucil (low certainty).
It is very uncertain whether cyclophosphamide changes adverse effects: severe infection compared with chlorambucil (very low certainty).
It is very uncertain whether cyclophosphamide changes adverse effects: hair loss compared with chlorambucil (very low certainty).
Rituximab showed no clear difference in adverse effects: arthropathy compared with placebo or control (low certainty).
Mycophenolate mofetil showed no clear difference in relapses at 12 months compared with levamisole (low certainty).
Systemic corticosteroid probably leads to lower end‐stage kidney disease compared with no corticosteroid regimen (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether cytotoxic regimen changes death (any cause) compared with no cytotoxic regimen (very low certainty).
It is very uncertain whether cytotoxic regimen changes infection compared with no cytotoxic regimen (very low certainty).
It is very uncertain whether cytotoxic regimen changes malignancy compared with no cytotoxic regimen (very low certainty).